Skip to main content
. 2002 Jul 18;99(16):10276–10281. doi: 10.1073/pnas.102327699

Fig 2.

Fig 2.

(A) Cross-desensitization of the μ-opioid response of monocytes after CCL5 pretreatment. Monocytes were either untreated (•) or pretreated with CCL5 (▾; 100 ng/ml) for 60 min, and the response to the μ-opioid agonist DAMGO was determined. The response of CCL5 pretreated cells to CCL5 (50 ng/ml) is also shown. (B) Cross-desensitization of the μ-opioid response of the HaCaT keratinocyte cell line after CCL5 (▴; 100 ng/ml), CCL19 (▵; 100 ng/ml), or CXCL12 (♦; 100 ng/ml) pretreatment. Nontreated cells (circles) and CXCL12-pretreated cells exhibit significant (P < 0.05) responses over the 0.1–10 nM range of DAMGO doses. (C) Cross-desensitization of the μ-opioid response of murine thymocytes without treatment (•) or following pretreatment (100 ng/ml) with CCL5 (▴), CCL2 (▾), CCL19 (⋄), and CXCL12 (▪). The data are representative of eight independent experiments.